US EditionNew Treatment Option for Relapsed or Refractory Hodgkin Lymphoma – Deutsches Ärzteblatt
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Chicago – Patients with relapsed or refractory Hodgkin lymphoma typically face a very poor prognosis. To date, there are few effective treatment options. A bispecific antibody combined with natural killer cells derived from umbilical cord blood has shown significant efficacy in a Phase 2 trial presented at the annual meeting of the...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
